Table 2. Odds ratio (95% confidence interval) of incident cognitive impairment according to baseline fibroblast growth factor 23 concentrations.
| FGF23 Quartile 1(<53 RU/ml) | FGF23 Quartile 2(53–69.9 RU/ml) | FGF23 Quartile 3(70–100 RU/ml) | FGF23 Quartile 4(>100 RU/ml) | Per doubling of FGF23 | |
|---|---|---|---|---|---|
| Events | 94 | 118 | 115 | 147 | 474 |
| Model 1 | ref | 1.27 (0.89, 1.83) | 1.31 (0.91, 1.87) | 1.73 (1.21, 2.47) | 1.12 (1.03, 1.33) |
| Model 2 | ref | 1.35 (0.89, 2.05) | 1.13 (0.73, 1.74) | 1.19 (0.76, 1.84) | 1.01 (0.87, 1.18) |
| Model 3 | ref | 1.23 (0.80, 1.89) | 1.08 (0.68, 1.72) | 1.04 (0.63, 1.72) | 0.99 (0.81, 1.23) |
Model 1 is unadjusted; Model 2 is adjusted for geographic region of residence, annual income, diabetes status, history of coronary heart disease, current smoking and depressive symptoms; Model 3 is adjusted for variables in model 2 plus estimated glomerular filtration rate, log-transformed albumin to creatinine ratio, phosphorus, calcium, and parathyroid hormone.